Isolation and in vitro susceptibility to amphoterecin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus

E. K. Manavathu, O. C. Abraham, P. H. Chandrasekar

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objectives. To select voriconazole-resistant mutants of Aspergillus fumigatus in the laboratory from drug-susceptible clinical isolates and examine their in vitro susceptibility to amphotericin B and investigational azoles, and to compare the intramycelial accumulation of voriconazole in the resistant isolates with that in the susceptible parent. Methods. Voriconazole-resistant Aspergillus fumigatus isolates were selected in the laboratory from three highly susceptible (MIC ≤ 0.5 mg/L) clinical isolates by stepwise selection on peptone yeast extract glucose (PYG) agar containing 0.5 mg and 4 mg voriconazole/L. Twenty-three colonies that grew in the presence of 4 mg voriconazole/L on PYG agar (frequency 1.9 × 10-8) were tested for their in vitro susceptibility to amphotericin B, itraconazole, voriconazole and posaconazole by a broth macrodilution technique. The accumulation of voriconazole in the mycelia of two representative resistant isolates (VCZ-W42 and VCZ-W45) was determined by a previously described bioassay. Results. The geometric mean MICs (mg/L) of amphotericin B, itraconazole, voriconazole and posaconazole for these isolates were 0.45 ± 0.19, 0.69 ± 0.45, 5.24 ± 3.74 and 0.27 ± 0.18, respectively. A comparison of the geometric mean MICs of the antifungals obtained for the resistant isolates to those of the susceptible parents showed 1.15-, 2.76-, 16.90- and 1.42-fold increases, respectively, for amphotericin B, itraconazole, voriconazole and posaconazole, suggesting that low-level cross-resistance exists between the azole antifungals. The susceptible parent and the resistant isolates accumulated similar amounts of voriconazole. Conclusions. These results suggest that spontaneous mutants of Aspergillus fumigatus resistant to voriconazole could emerge among clinical isolates under selection pressure and that the observed reduced in vitro susceptibility to voriconazole may not be due to reduced accumulation of the drug in the mycelia.

Original languageEnglish (US)
Pages (from-to)130-137
Number of pages8
JournalClinical Microbiology and Infection
Volume7
Issue number3
DOIs
StatePublished - Mar 2001

Fingerprint

Aspergillus fumigatus
Itraconazole
Amphotericin B
Azoles
Peptones
Mycelium
Agar
In Vitro Techniques
posaconazole
Voriconazole
Yeasts
Glucose
Biological Assay
Pharmaceutical Preparations

Keywords

  • Antifungal resistance
  • Aspergillus fumigatus
  • Posaconazole
  • Susceptibility studies
  • Vorioconazole

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Isolation and in vitro susceptibility to amphoterecin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. / Manavathu, E. K.; Abraham, O. C.; Chandrasekar, P. H.

In: Clinical Microbiology and Infection, Vol. 7, No. 3, 03.2001, p. 130-137.

Research output: Contribution to journalArticle

@article{bfabba563d3f4f1dbc98f47f06496357,
title = "Isolation and in vitro susceptibility to amphoterecin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus",
abstract = "Objectives. To select voriconazole-resistant mutants of Aspergillus fumigatus in the laboratory from drug-susceptible clinical isolates and examine their in vitro susceptibility to amphotericin B and investigational azoles, and to compare the intramycelial accumulation of voriconazole in the resistant isolates with that in the susceptible parent. Methods. Voriconazole-resistant Aspergillus fumigatus isolates were selected in the laboratory from three highly susceptible (MIC ≤ 0.5 mg/L) clinical isolates by stepwise selection on peptone yeast extract glucose (PYG) agar containing 0.5 mg and 4 mg voriconazole/L. Twenty-three colonies that grew in the presence of 4 mg voriconazole/L on PYG agar (frequency 1.9 × 10-8) were tested for their in vitro susceptibility to amphotericin B, itraconazole, voriconazole and posaconazole by a broth macrodilution technique. The accumulation of voriconazole in the mycelia of two representative resistant isolates (VCZ-W42 and VCZ-W45) was determined by a previously described bioassay. Results. The geometric mean MICs (mg/L) of amphotericin B, itraconazole, voriconazole and posaconazole for these isolates were 0.45 ± 0.19, 0.69 ± 0.45, 5.24 ± 3.74 and 0.27 ± 0.18, respectively. A comparison of the geometric mean MICs of the antifungals obtained for the resistant isolates to those of the susceptible parents showed 1.15-, 2.76-, 16.90- and 1.42-fold increases, respectively, for amphotericin B, itraconazole, voriconazole and posaconazole, suggesting that low-level cross-resistance exists between the azole antifungals. The susceptible parent and the resistant isolates accumulated similar amounts of voriconazole. Conclusions. These results suggest that spontaneous mutants of Aspergillus fumigatus resistant to voriconazole could emerge among clinical isolates under selection pressure and that the observed reduced in vitro susceptibility to voriconazole may not be due to reduced accumulation of the drug in the mycelia.",
keywords = "Antifungal resistance, Aspergillus fumigatus, Posaconazole, Susceptibility studies, Vorioconazole",
author = "Manavathu, {E. K.} and Abraham, {O. C.} and Chandrasekar, {P. H.}",
year = "2001",
month = "3",
doi = "10.1046/j.1469-0691.2001.00220.x",
language = "English (US)",
volume = "7",
pages = "130--137",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Isolation and in vitro susceptibility to amphoterecin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus

AU - Manavathu, E. K.

AU - Abraham, O. C.

AU - Chandrasekar, P. H.

PY - 2001/3

Y1 - 2001/3

N2 - Objectives. To select voriconazole-resistant mutants of Aspergillus fumigatus in the laboratory from drug-susceptible clinical isolates and examine their in vitro susceptibility to amphotericin B and investigational azoles, and to compare the intramycelial accumulation of voriconazole in the resistant isolates with that in the susceptible parent. Methods. Voriconazole-resistant Aspergillus fumigatus isolates were selected in the laboratory from three highly susceptible (MIC ≤ 0.5 mg/L) clinical isolates by stepwise selection on peptone yeast extract glucose (PYG) agar containing 0.5 mg and 4 mg voriconazole/L. Twenty-three colonies that grew in the presence of 4 mg voriconazole/L on PYG agar (frequency 1.9 × 10-8) were tested for their in vitro susceptibility to amphotericin B, itraconazole, voriconazole and posaconazole by a broth macrodilution technique. The accumulation of voriconazole in the mycelia of two representative resistant isolates (VCZ-W42 and VCZ-W45) was determined by a previously described bioassay. Results. The geometric mean MICs (mg/L) of amphotericin B, itraconazole, voriconazole and posaconazole for these isolates were 0.45 ± 0.19, 0.69 ± 0.45, 5.24 ± 3.74 and 0.27 ± 0.18, respectively. A comparison of the geometric mean MICs of the antifungals obtained for the resistant isolates to those of the susceptible parents showed 1.15-, 2.76-, 16.90- and 1.42-fold increases, respectively, for amphotericin B, itraconazole, voriconazole and posaconazole, suggesting that low-level cross-resistance exists between the azole antifungals. The susceptible parent and the resistant isolates accumulated similar amounts of voriconazole. Conclusions. These results suggest that spontaneous mutants of Aspergillus fumigatus resistant to voriconazole could emerge among clinical isolates under selection pressure and that the observed reduced in vitro susceptibility to voriconazole may not be due to reduced accumulation of the drug in the mycelia.

AB - Objectives. To select voriconazole-resistant mutants of Aspergillus fumigatus in the laboratory from drug-susceptible clinical isolates and examine their in vitro susceptibility to amphotericin B and investigational azoles, and to compare the intramycelial accumulation of voriconazole in the resistant isolates with that in the susceptible parent. Methods. Voriconazole-resistant Aspergillus fumigatus isolates were selected in the laboratory from three highly susceptible (MIC ≤ 0.5 mg/L) clinical isolates by stepwise selection on peptone yeast extract glucose (PYG) agar containing 0.5 mg and 4 mg voriconazole/L. Twenty-three colonies that grew in the presence of 4 mg voriconazole/L on PYG agar (frequency 1.9 × 10-8) were tested for their in vitro susceptibility to amphotericin B, itraconazole, voriconazole and posaconazole by a broth macrodilution technique. The accumulation of voriconazole in the mycelia of two representative resistant isolates (VCZ-W42 and VCZ-W45) was determined by a previously described bioassay. Results. The geometric mean MICs (mg/L) of amphotericin B, itraconazole, voriconazole and posaconazole for these isolates were 0.45 ± 0.19, 0.69 ± 0.45, 5.24 ± 3.74 and 0.27 ± 0.18, respectively. A comparison of the geometric mean MICs of the antifungals obtained for the resistant isolates to those of the susceptible parents showed 1.15-, 2.76-, 16.90- and 1.42-fold increases, respectively, for amphotericin B, itraconazole, voriconazole and posaconazole, suggesting that low-level cross-resistance exists between the azole antifungals. The susceptible parent and the resistant isolates accumulated similar amounts of voriconazole. Conclusions. These results suggest that spontaneous mutants of Aspergillus fumigatus resistant to voriconazole could emerge among clinical isolates under selection pressure and that the observed reduced in vitro susceptibility to voriconazole may not be due to reduced accumulation of the drug in the mycelia.

KW - Antifungal resistance

KW - Aspergillus fumigatus

KW - Posaconazole

KW - Susceptibility studies

KW - Vorioconazole

UR - http://www.scopus.com/inward/record.url?scp=0035295450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035295450&partnerID=8YFLogxK

U2 - 10.1046/j.1469-0691.2001.00220.x

DO - 10.1046/j.1469-0691.2001.00220.x

M3 - Article

C2 - 11318811

AN - SCOPUS:0035295450

VL - 7

SP - 130

EP - 137

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 3

ER -